{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:35:36Z","timestamp":1794591336441,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adding a PD-1\/PD-L1 inhibitor to gemcitabine plus cisplatin (GemCis) has shown survival benefits in advanced biliary tract cancer (BTC). Dual inhibition of PD-1\/PD-L1 and TIGIT may act synergistically, and further enhance antitumor effects. ZSAB-TOP was a single-arm, multicenter, phase 2 study (NCT05023109) evaluating efficacy and safety of first-line tislelizumab (a PD-1 inhibitor) plus ociperlimab (a TIGIT inhibitor) and GemCis in advanced BTC. Eligible patients received tislelizumab (200\u2009mg) and ociperlimab (900\u2009mg) on day 1 until unacceptable toxicity or disease progression, in combination with cisplatin (25\u2009mg\/m\u00b2) and gemcitabine (1000\u2009mg\/m\u00b2) on days 1 and 8 of a 21-day cycle for a maximum eight cycles. The primary endpoint was confirmed objective response rate (ORR) evaluated by the investigator, which was compared with a historical ORR of 25% with GemCis, with a statistical superiority setting at p\u2009\u2264\u20090.05. From March 8, 2022, to January 18, 2023, 45 patients were enrolled. Among the 41 patients in the efficacy analysis set, the confirmed ORR was 51.2% (95% CI 35.1\u201367.1), achieving the statistical superiority criteria (p\u2009=\u20090.0003). Patients who had TIGIT\n                    <jats:sup>+<\/jats:sup>\n                    \/PD-L1\n                    <jats:sup>+<\/jats:sup>\n                    (n\u2009=\u200916) tended to have a numerically greater confirmed ORR (75.0% [95% CI 47.6\u201392.7]). After a median follow-up of 14.6 months, median progression-free survival was 7.7 months (95% CI 6.0\u20139.4), with a median overall survival of 17.4 months (95% CI 11.7-not reached). Treatment-related adverse events of grade \u22653 occurred in 60.0% of patients; immune-mediated adverse events of any grade was observed in 42.2%, with the majority being grade 1 or 2. In conclusion, first-line tislelizumab and ociperlimab plus GemCis yielded clinically promising tumor response and survival outcomes in advanced BTC and were generally well tolerated without new safety signals.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02356-y","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T23:01:57Z","timestamp":1755730917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study"],"prefix":"10.1038","volume":"10","author":[{"given":"Guoming","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-6396","authenticated-orcid":false,"given":"Jianhong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangjian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6613-8270","authenticated-orcid":false,"given":"Zhenbin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiman","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-1117","authenticated-orcid":false,"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-629X","authenticated-orcid":false,"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2356_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"2356_CR2","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/CM9.0000000000002258","volume":"135","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019. Chin. Med J. (Engl.) 135, 1697\u20131706 (2022).","journal-title":"Chin. Med J. (Engl.)"},{"key":"2356_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jjco\/hyu210","volume":"45","author":"JH Ji","year":"2015","unstructured":"Ji, J. H. et al. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). Jpn J. Clin. Oncol. 45, 256\u2013260 (2015).","journal-title":"Jpn J. Clin. Oncol."},{"key":"2356_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med"},{"key":"2356_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4143\/crt.2014.308","volume":"47","author":"JO Park","year":"2015","unstructured":"Park, J. O. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat. 47, 343\u2013361 (2015).","journal-title":"Cancer Res Treat."},{"key":"2356_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/CM9.0000000000002759","volume":"137","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y., Yang, M., Feng, J., Wang, X. & Liu, Y. Advances in immunotherapy for biliary tract cancers. Chin. Med J. (Engl.) 137, 524\u2013532 (2024).","journal-title":"Chin. Med J. (Engl.)"},{"key":"2356_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh, D. Y. et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomized phase 3 study. Lancet Gastroenterol. Hepatol. 9, 694\u2013704 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2356_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"2356_CR9","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge, Z., Peppelenbosch, M. P., Sprengers, D. & Kwekkeboom, J. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Front Immunol. 12, 699895 (2021).","journal-title":"Front Immunol."},{"key":"2356_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates coblockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55, 512\u2013526.e519 (2022).","journal-title":"Immunity"},{"key":"2356_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T-cell effector function. Cancer Cell 26, 923\u2013937 (2014).","journal-title":"Cancer Cell"},{"key":"2356_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomized, double-blind, phase 2 study. Lancet Oncol. 23, 781\u2013792 (2022).","journal-title":"Lancet Oncol."},{"key":"2356_CR13","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2023.41.16_suppl.4010","volume":"41","author":"RS Finn","year":"2023","unstructured":"Finn, R. S. et al. The results from the MORPHEUS-liver study: Phase Ib\/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). J. Clin. Oncol. 41, 4010\u20134010 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2356_CR14","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1538-7445.AM2021-1854","volume":"81","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. J. Cancer Res 81, 1854 (2021).","journal-title":"J. Cancer Res"},{"key":"2356_CR15","doi-asserted-by":"publisher","first-page":"e005829","DOI":"10.1136\/jitc-2022-005829","volume":"11","author":"S Frentzas","year":"2023","unstructured":"Frentzas, S. et al. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. J. Immunother. Cancer 11, e005829 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2356_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka, T. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan. Br. J. Cancer 103, 469\u2013474 (2010).","journal-title":"Br. J. Cancer"},{"key":"2356_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"2356_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu, X., Tian, W., Wang, Z., Zhang, J. & Zhou, R. Coinhibition of TIGIT and PD-1\/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. Mol. Cancer 22, 93 (2023).","journal-title":"Mol. Cancer"},{"key":"2356_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000527175","volume":"12","author":"Z Ren","year":"2023","unstructured":"Ren, Z. et al. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer 12, 72\u201384 (2023).","journal-title":"Liver Cancer"},{"key":"2356_CR20","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 9, 1651\u20131659 (2023).","journal-title":"JAMA Oncol."},{"key":"2356_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang, T. et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol. Immunother. 67, 1079\u20131090 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"2356_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.23.01363","volume":"42","author":"CM Rudin","year":"2024","unstructured":"Rudin, C. M. et al. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J. Clin. Oncol. 42, 324\u2013335 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2356_CR23","doi-asserted-by":"crossref","unstructured":"Acheampong, E. et al. Tumor PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells 9, (2020).","DOI":"10.3390\/cells9112393"},{"key":"2356_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00300-9","volume":"6","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. NPJ Precis Oncol. 6, 58 (2022).","journal-title":"NPJ Precis Oncol."},{"key":"2356_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","volume":"43","author":"Y Qiao","year":"2023","unstructured":"Qiao, Y. et al. Enhancement of CAR-T-cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Commun. (Lond.) 43, 788\u2013807 (2023).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2356_CR26","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8\u207a T cells in melanoma patients. J. Clin. Invest 125, 2046\u20132058 (2015).","journal-title":"J. Clin. Invest"},{"key":"2356_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2020.11.035","volume":"499","author":"HS Han","year":"2021","unstructured":"Han, H. S. et al. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by coblockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 499, 137\u2013147 (2021).","journal-title":"Cancer Lett."},{"key":"2356_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fonc.2019.01066","volume":"9","author":"X Li","year":"2019","unstructured":"Li, X. et al. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. Front Oncol. 9, 1066 (2019).","journal-title":"Front Oncol."},{"key":"2356_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J. Thorac. Oncol. 18, 93\u2013105 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2356_CR30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","volume":"9","author":"TW Kim","year":"2023","unstructured":"Kim, T. W. et al. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a\/1b Nonrandomized Controlled Trial. JAMA Oncol. 9, 1574\u20131582 (2023).","journal-title":"JAMA Oncol."},{"key":"2356_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca, A., Barriuso, J., McNamara, M. G. & Valle, J. W. Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer. J. Hepatol. 73, 170\u2013185 (2020).","journal-title":"J. Hepatol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02356-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02356-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02356-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:49:59Z","timestamp":1757468999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02356-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2356"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02356-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}